



Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders

ANN ARBOR, Mich., Oct 31, 2007 (BUSINESS WIRE) -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast:

What: Aastrom Biosciences Fiscal Year 2007 Annual Meeting of Shareholders

When: Wednesday, November 7, 2007 @ 9:00 am (Eastern)

Where: <http://www.vcall.com/IC/CEPage.asp?ID=122044>

How: For live Internet access, simply log on to the web at the link above. Shareholders and other interested parties will be able to listen to the entire Annual Meeting of Shareholders. After the business portion of the meeting, Aastrom will present a corporate slideshow update. Only shareholders in attendance at the meeting will be able to participate in the Question & Answer session.

Contact: Kris Maly, Investor Relations Department, (734) 930-5777 or mail@aastrom.com

If you are unable to listen to the live webcast, a replay of the meeting will be archived at <http://www.investorcalendar.com/> until January 31, 2008.

About Aastrom Biosciences, Inc.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The company's proprietary Tissue Repair Cell (TRC) Technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting bone, vascular, cardiac, and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC Technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the company has a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a vascular regeneration product in clinical development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), and preclinical research programs targeting unmet needs in cardiac and neural health. Aastrom product candidates to treat osteonecrosis of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the FDA. For more information, visit Aastrom's website at www.aastrom.com. (astmc)

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences
Kris Maly, Investor Relations Department, 734-930-5777
mail@aastrom.com

Copyright Business Wire 2007

News Provided by COMTEX